This is a prospective cohort study aimed at clarifying the predictive value of MRD for postoperative DFS and OS in high-risk recurrent renal cell carcinoma patients who have undergone radical nephrectomy and received adjuvant treatment with Toripalimab. Further differentiating patients who need adjuvant immunotherapy.
There must be a histological diagnosis of renal cell carcinoma, with or without sarcomatoid features of clear cell components.
On the day of signing the informed consent form, both males and females must be at least 18 years old.
The participants provide written informed consent for the trial before enrollment.
Have high risk or M1 NED renal cell carcinoma as defined by the following pathological tumor-node-metastasis and Fuhrman grading status.
None